AbbVie Inc.

News & Events

Press Releases

In The Media

1. AbbVie Reports Third-Quarter 2025 Financial Results

   PR Newswire OCT 31, 2025 7:49 AM EDT
   AbbVie Reports Third-Quarter 2025 Financial Results PR Newswire Reports Third-Qua...
   Read Article

2. ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

   Canada Newswire OCT 30, 2025 7:01 AM EDT
   ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain ...
   Read Article

3. The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

   PR Newswire OCT 29, 2025 5:00 PM EDT
   The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Big...
   Read Article

4. AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

   PR Newswire OCT 29, 2025 8:11 AM EDT
   AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (R...
   Read Article

5. Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM

   PR Newswire OCT 28, 2025 9:00 AM EDT
   Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders ...
   Read Article

6. The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

   PR Newswire OCT 21, 2025 8:00 AM EDT
   The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Rec...
   Read Article

7. RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor

   PR Newswire OCT 20, 2025 8:00 AM EDT
   RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary...
   Read Article

8. AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

   PR Newswire OCT 17, 2025 9:00 AM EDT
   AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin PR Newswire ...
   Read Article

9. U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

   PR Newswire OCT 13, 2025 10:57 AM EDT
   U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (u...
   Read Article

10. AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

    PR Newswire OCT 13, 2025 7:15 AM EDT
    AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies fo...
    Read Article